Julia Wilson

Research and career After earning her doctorate, Wilson moved to the Karolinska Institute as a postdoctoral researcher where she worked alongside Hans-Gustaf Ljunggren on transplant rejection. Whilst Wilson enjoyed working in Sweden, she has said that she initially lost confidence during her time in Stockholm because she was less experienced than her colleagues. During her time at Breakthrough, the charity discovered PARP inhibitors, target cancer drugs that can be used to treat ovarian cancer. She was selected to take park in a clinical placement course, during which time she shadowed a medical team. The placement was designed to bridge the gap between clinical science and patient care. The placement made her aware of the disconnect between drug discovery and the clinic.

Selected publications Her publications include: Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells